reports
Agrify Corporation Mutually Agrees to Terminate Plan to Merge with Nat...
Agrify Corporation Mutually Agrees to Terminate Plan to Merge with Nature’s Miracle TROY, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq:AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that Agrify Corporation and Nature’s Miracle Holdings Inc. (NASDAQ: NMHI) (“Nature’s Miracle”) have mutually agreed to terminate the agreement and plan of merger, previously announced on May 16, 2024, given unfavorable market conditions. In connection with the termination of the mer...
New Study Published in JCO Precision Oncology Shows Myriad Genetics' P...
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation t...
Nature’s Miracle and Agrify Corporation Announces Signing of the Defin...
Nature’s Miracle and Agrify Corporation Announces Signing of the Definitive Merger Agreement Transaction Expected to Close in the Second Half of 2024 ONTARIO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Nature's Miracle Holding Inc. (NASDAQ: NMHI; NMHIW) (“Nature’s Miracle” or the “Company”), a leader in vertical farming technology and infrastructure, and Agrify Corporation (NASDAQ: AGFY) (“Agrify”), announced today that both parties have signed a definitive agreement and plan of merger (“Agreement”) in which a new wholly-owned subsidiary of Nature’s Miracle will merge with and into Agrify...
- Matt Quigley
- Tom Nikic
Nike Inc: 1 director
A director at Nike Inc gave away/sold after exercising options/sold 186,755 shares at 0.000USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 K...
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 24...
Globus Medical Inc: 1 director
A director at Globus Medical Inc sold/sold after exercising options 63,300 shares at 64.613USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
First Solar Inc: 1 director
A director at First Solar Inc sold 7,150 shares at 190.715USD and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Atossa Therapeutics Announces First Quarter 2024 Financial Results and...
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. ...
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
RM REGIONAL MANAGEMENT CORP
RHP RYMAN HOSPITALITY PROPERTIES INC.
PENN PENN NATIONAL GAMING INC.
LTRX LANTRONIX INC.
KMPR KEMPER CORPORATION
HUBB HUBBELL INCORPORATED CLASS B
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
CTRN CITI TRENDS INC.
CNMD CONMED CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
AMH AMERICAN HOMES 4 RENT CLASS A
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
EFR ENERGY FUELS
SABR SABRE CORP.
ALPN ALPINE SELECT AG
HTLD HEARTLAND EXPRESS INC.
MAC MACERICH COMPANY
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
WDFC WD-40 COMPANY
PK PARK HOTELS & RESORTS INC.
CRVS CORVUS PHARMACEUTICALS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EAF GRAFTECH INTERNATIONAL
FRAF FRANKLIN FINANCIAL SERVICES CO.
BBDC BARINGS BDC INC.
GH GUARDANT HEALTH
MCFT MASTERCRAFT BOAT HOLDINGS
HQL TEKLA LIFE SCIENCES INVESTORS
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
PSTV PLUS THERAPEUTICS INC
CTOS CUSTOM TRUCK ONE SOURCE
TBBK INC.
MEGI THE BANCORP
NPCT INC.
RXO_w MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
BYON NUVEEN CORE PLUS IMPACT FD
VSTS_w RXO INC
NBBK BEYON 3D LTD
ASGI VESTIS CORPORATION
EYPT NB BANCORP INC.
DBD ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
EYEPOINT PHARMACEUTICALS
INC.
DIEBOLD NIXDORF INCORPORATED
Regional Management Corp: 1 director
A director at Regional Management Corp bought 72,546 shares at 30.248USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
- Matt Quigley
- Tom Nikic
- Wedbush Research
MTB M&T BANK CORPORATION
STZ CONSTELLATION BRANDS INC. CLASS A
UBI UBISOFT ENTERTAINMENT SA
DPZ DOMINO'S PIZZA INC.
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PEGA PEGASYSTEMS INC.
MGPI MGP INGREDIENTS INC.
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FHN FIRST HORIZON CORPORATION
EPAM EPAM SYSTEMS INC.
DECK DECKERS OUTDOOR CORPORATION
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
OSTK OVERSTOCK.COM INC.
WD WALKER & DUNLOP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
TENB TENABLE HOLDINGS
BROS DUTCH BROS INC
Tecnoglass Reports First Quarter 2024 Results
Tecnoglass Reports First Quarter 2024 Results - Revenue of $192.6 Million - - Net Income of $29.7 Million, or $0.63 Per Diluted Share - - Adjusted Net Income1 of $30.9 Million, or $0.66 Per Diluted Share - - Adjusted EBITDA1 of $51.0 Million, Representing 26.5% of Revenues - - Strong Cash Flow from Operations of $33.4 Million, Representing 65% of Adjusted EBITDA1 - - All Time Record Low Net Leverage Ratio of 0.1x at Quarter End - - Backlog Continues Record Trajectory, Expanding 18% Year-Over-Year to $916 Million - ...
- Jonathan Moreland
RM REGIONAL MANAGEMENT CORP
PENN PENN NATIONAL GAMING INC.
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
CNMD CONMED CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
AMH AMERICAN HOMES 4 RENT CLASS A
EFR ENERGY FUELS
MAC MACERICH COMPANY
CTOS CUSTOM TRUCK ONE SOURCE
TBBK INC.
VSTS_w THE BANCORP
EYPT INC.
VESTIS CORPORATION
EYEPOINT PHARMACEUTICALS
INC.
Globus Medical Reports First Quarter 2024 Results
Globus Medical Reports First Quarter 2024 Results AUDUBON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024. Worldwide net sales were $606.7 million, an increase of 119.3%, or 119.8% on a constant currency basisGAAP net loss for the quarter was $7.1 millionGAAP diluted earnings per share (“EPS”) was ($0.05) and non-GAAP diluted EPS was $0.72Non-GAAP adjusted EBITDA was $166.6 million, or 27.5% of net sales “Since the NuVasive merger closed in Se...
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; A...
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year period, reflecting no-pay reduction efforts.First quarter GAAP net loss of $26 million and positive adjusted EBITDA of $4 million; net loss and adjusted EBITDA improve...
Myriad Genetics Announces Reorganization of European Operations and Sa...
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United States. As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro med...
Atossa Therapeutics Announces Support of New Breast Cancer Screening G...
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The updated guidelines recommend women undergo bi...
Bioventus Reports First Quarter Financial Results
Bioventus Reports First Quarter Financial Results Raises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic PrioritiesAccelerated First Quarter Revenue Growth by 8.7%, Organic Growth* by 15.3%Gross Margin Expanded 620 bps and Adjusted Gross Margin* 190 bps DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024. “We are pleased with the strong start to the year...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.